Table D-12. Evidence table for studies addressing management of PPH (Zatta 2014)

| **Study** **Description** | **Intervention** | **Inclusion/Exclusion** **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| **Author:**Zatta et al., 201415**Country:**Australia and New Zealand**Enrollment period:** 2000 to 2009**Birth setting:** NR**Facility characteristics:** 96 hospitals d, 75 reported off-label use of rFVIIa**Funding:**Unrestricted educational grant from Novo Nordisk Pharmaceuticals (makers of rFVIIa)**Design:** Registry- case series | **Intervention:** Received rFVIIa for off-label indication- subset of registry cases who received it for obstetric hemorrhage**Groups:****G1:** intervention**N: 3446 cases of off-label use of rFVIIa, 177 obstetric cases****G1:** 175 patients (177 cases)**Duration of treatment:** NR**Timing of treatment:** NR**Order of treatment:** NR**Length of follow-up:**up to 28 days following rFVIIa administration | **Operational definition of PPH:** NR**Definition of success of treatment:** NR**Method of blood loss measurement:** NR**Severity:** NR**Inclusion criteria:** Registry patients receiving rFVIIa to preempt or treat clinical bleeding episodes outside the approved indicationscriterion 2**Exclusion criteria:** patients with acquired hemophilia**Maternal age, yrs, mean ± SD:** NR **Parity, n:** NR**Weeks gestation, n (%):** NR**Single pregnancy, n (%):** NR**Multiple pregnancy, n (%):** NR**Race/ethnicity:** NR**BMI:** NR**Baseline hemoglobin:** NR**SES:** NR**Mode of birth, n:** NR**Risk factors, n (%):** NR**Primary etiology of PPH, n (%):** Atony**G1:** 39Placenta previa**G1:** 46Placenta accreta/percreta**G1:** 30Intrauterine fetal death**G1:** 23Preeclampsia/Eclampsia**G1:** 20Placental abruption**G1:** 17Other**G1:** 2 | **Harms pre-specified:** 28-day mortality**Harms, n (%):** 28-day mortality**G1:** 11 (6)Total with thromboembolic adverse events**G1:** 15 (8.6)Arterial thrombosis**G1:** 2 (1.1)Cerebrovascular accident**G1:** 1 (0.6)Acute myocardial infarction**G1:** 1 (0.6)Venous thrombosis**G1:** 5 (2.9)Deep vein thrombosis**G1:** 1 (0.6) Pulmonary embolism**G1:** 1 (0.6)Other thrombosis**G1:** 3 (1.7)Patients with DIC**G1:** 9 (5.1)Stroke**G1:** 0 (0) |